Premium
P3‐425: ALZHEIMER'S DEMENTIA CONVERSION IN AMNESTIC MCI ACCORDING TO NEUROPSYCHOLOGICAL PROFILE
Author(s) -
Jung Young Hee,
Kim Hee Jin,
Seo Sang Won,
Kim Yeshin,
Jang Hyemin,
Cho Su Hyun,
Kim Seung Joo,
Kim Si Eun,
Chin Juhee,
Kim Sung Tae,
Na Duk L.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.1788
Subject(s) - dementia , audiology , neuropsychology , cognition , atrophy , psychology , cognitive impairment , magnetic resonance imaging , medicine , cardiology , neuroscience , radiology , disease
annualized change in SUVR were compared between DLB and CN using generalized additive models accounting for matching. Associations between annualized global measures of clinical progression and b-amyloid accumulation were assessed in DLB. Results: The trajectories of longitudinal b-amyloid accumulation were similar between DLB and CN (p1⁄40.425 for difference in trajectory shape; p1⁄40.22 for difference in vertical shift; Figure 1). Rates of b-amyloid accumulation increased up to 1.8 baseline SUVR and then decreased. Increasing changes in clinical dementia rating -sum of boxes were independently associated with higher baseline SUVR (p1⁄40.023) and a greater change in SUVR (p1⁄40.025) until reaching 1.8 baseline SUVR; no relationship was present for >1.8 baseline SUVR (Figure 2). Conclusions: In DLB, b-amyloid accumulation accelerates and is associated with clinical decline up to 1.8 baseline SUVR. At >1.8 baseline SUVR, the accumulation decelerates and dissociates from the clinical progression. Acceleration–deceleration denotes a sigmoid-shaped functional form which is the same in unimpaired, clinical AD dementia, and as we have shown in DLB. Baseline PiB SUVR should be considered in designing clinical trials targeting b-amyloid pathology in DLB.